Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Lieske H. Schrijver; Antonis C. Antoniou; Håkan Olsson; Thea M. Mooij; Marie-José Roos-Blom; Leyla Azarang; Julian Adlard; Munaza Ahmed; Daniel Barrowdale; Rosemarie Davidson; Alan Donaldson; Ros Eeles; D. Gareth Evans; Debra Frost; Alex Henderson; Louise Izatt; Kai-Ren Ong; Valérie Bonadona; Isabelle Coupier; Laurence Faivre; Jean-Pierre Fricker; Paul Gesta; Klaartje van Engelen; Agnes Jager; Fred H. Menko; Marian J.E. Mourits; Christian F. Singer; Yen Y. Tan; Lenka Foretova; Marie Navratilova; Rita K. Schmutzler; Carolina Ellberg; Anne-Marie Gerdes; Trinidad Caldes; Jacques Simard; Edith Olah; Anna Jakubowska; Johanna Rantala; Ana Osorio; John L. Hopper; Kelly-Anne Phillips; Roger L. Milne; Mary Beth Terry; Catherine Noguès; Christoph Engel; Karin Kast; David E. Goldgar; Flora E. van Leeuwen; Douglas F. Easton; Nadine Andrieu; Matti A. Rookus; Lilian Laborde; Pauline Pontois; Emanuelle Breysse; Margot Berline; Dominique Stoppa-Lyonnet; Marion Gauthier-Villars; Bruno Buecher; Chrystelle Colas; Olivier Caron; Emmanuelle Mouret-Fourme; Claire Saule; Christine Lasset; Sophie Dussard; Pascaline Berthet; Elisabeth Luporsi; Véronique Mari; Laurence Gladieff; Stéphanie Chieze-Valéro; Jessica Moretta; Hagay Sobol; François Eisinger; Cornel Popovici; Michel Longy; Louise Grivelli; Florent Soubrier; Patrick Benusiglio; Pascal Pujol; Carole Corsini; Marie-Emmanuelle Morin-Meschin; Alain Lortholary; Claude Adenis; Audrey Maillez; Tan Dat Nguyen; Capucine Delnatte; Caroline Abadie; Julie Tinat; Isabelle Tennevet; Christine Maugard; Yves-Jean Bignon; Mathilde Gay Bellile; Clotilde Penet; Hélène Dreyfus; Odile Cohen-Haguenauer; Brigitte Gilbert; Laurence Venat-Bouvet; Dominique Leroux; Clémentine Legrand; Hélène Zattara-Cannoni; Valérie Layet; Elodie Lacaze; Sandra Fert-Ferrer; Odile Bera; Brigitte Gilbert-Dussardier; David Tougeron; Hakima Lallaoui; M.A. Rookus; F.B.L. Hogervorst; F.E. van Leeuwen; M.A. Adank; M.K. Schmidt; D.J. Jenner; J.M. Collée; A.M.W. van den Ouweland; M.J. Hooning; I.A. Boere; C.J. van Asperen; P. Devilee; R.B. van der Luijt; T.C.T.E.F. van Cronenburg; M.R. Wevers; A.R. Mensenkamp; M.G.E.M. Ausems; M.J. Koudijs; I. van de Beek; K. van Engelen; J.J.P. Gille; E.B. Gómez García; M.J. Blok; M. de Boer; L.P.V. Berger; A.H. van der Hout; M.J.E. Mourits; Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International; G.H. de Bock; S. Siesling; J. Verloop; E.C. van den Broek

doi:10.1016/j.ajog.2021.01.014

Retour

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Article de revue

Avec comité de lecture

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Lieske H. Schrijver, Antonis C. Antoniou, Håkan Olsson, Thea M. Mooij, Marie-José Roos-Blom, Leyla Azarang, Julian Adlard, Munaza Ahmed, Daniel Barrowdale, Rosemarie Davidson, …

American journal of obstetrics and gynecology, Vol.225(1), pp.51.e1-51.e17

01/07/2021

DOI: https://doi.org/10.1016/j.ajog.2021.01.014

PMID: 33493488

Résumé

BRCA1

BRCA2

epidemiology

multivariate

observational

oral contraceptives

ovarian cancer

retrospective

risk

survival bias

Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in the general population are well established (approximately 50% risk reduction in ovarian cancer), the estimated risk reduction in mutation carriers is much less precise because of potential bias and small sample sizes. In addition, only a few studies on oral contraceptive use have examined the associations of duration of use, time since last use, starting age, and calendar year of start with risk of ovarian cancer. This study aimed to investigate in more detail the associations of various characteristics of oral contraceptive use and risk of ovarian cancer, to provide healthcare providers and carriers with better risk estimates. In this international retrospective study, ovarian cancer risk associations were assessed using oral contraceptives data on 3989 BRCA1 and 2445 BRCA2 mutation carriers. Age-dependent–weighted Cox regression analyses were stratified by study and birth cohort and included breast cancer diagnosis as a covariate. To minimize survival bias, analyses were left truncated at 5 years before baseline questionnaire. Separate analyses were conducted for each aspect of oral contraceptive use and in a multivariate analysis, including all these aspects. In addition, the analysis of duration of oral contraceptive use was stratified by recency of use. Oral contraceptives were less often used by mutation carriers who were diagnosed with ovarian cancer (ever use: 58.6% for BRCA1 and 53.5% BRCA2) than by unaffected carriers (ever use: 88.9% for BRCA1 and 80.7% for BRCA2). The median duration of use was 7 years for both BRCA1 and BRCA2 carriers who developed ovarian cancer and 9 and 8 years for unaffected BRCA1 and BRCA2 carriers with ovarian cancer, respectively. For BRCA1 mutation carriers, univariate analyses have shown that both a longer duration of oral contraceptive use and more recent oral contraceptive use were associated with a reduction in the risk of ovarian cancer. However, in multivariate analyses, including duration of use, age at first use, and time since last use, duration of oral contraceptive use proved to be the prominent protective factor (compared with <5 years: 5–9 years [hazard ratio, 0.67; 95% confidence interval, 0.40–1.12]; >10 years [hazard ratio, 0.37; 95% confidence interval, 0.19–0.73]; Ptrend=.008). The inverse association between duration of use and ovarian cancer risk persisted for more than 15 years (duration of ≥10 years; BRCA1 <15 years since last use [hazard ratio, 0.24; 95% confidence interval, 0.14–0.43]; BRCA1 >15 years since last use [hazard ratio, 0.56; 95% confidence interval, 0.18–0.59]). Univariate results for BRCA2 mutation carriers were similar but were inconclusive because of limited sample size. For BRCA1 mutation carriers, longer duration of oral contraceptive use is associated with a greater reduction in ovarian cancer risk, and the protection is long term.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study
Créateurs - sans rôle: Lieske H. Schrijver - Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Antonis C. Antoniou - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
Håkan Olsson - Lund University
Thea M. Mooij - The Netherlands Cancer Institute
Marie-José Roos-Blom - Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Leyla Azarang - Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Julian Adlard - Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, United Kingdom
Munaza Ahmed - Great Ormond Street Hospital for Children NHS Foundation Trust
Daniel Barrowdale - University of Cambridge
Rosemarie Davidson - University of Glasgow
Alan Donaldson - Department of Clinical Genetics, St. Michael’s Hospital, Bristol, United Kingdom
Ros Eeles - Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom
D. Gareth Evans - Division of Evolution and Genomic Sciences, Department of Genomic Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Debra Frost - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
Alex Henderson - Centre for Life, Institute of Genetic Medicine, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom
Louise Izatt - Guy's and St Thomas' NHS Foundation Trust
Kai-Ren Ong - Birmingham Women’s and Children’s NHS Foundation Trust
Valérie Bonadona - Université Claude Bernard Lyon 1
Isabelle Coupier - Hôpital Arnaud de Villeneuve
Laurence Faivre - Genomic and Immunotherapy Medical Institute
Jean-Pierre Fricker - Unité d’ Oncogénétique, Centre Paul Strauss, Strasbourg, France
Paul Gesta - Service d’Oncogénétique Régional Poitou-Charentes, Centre Hospitalier Georges Renon, Niort, France
Klaartje van Engelen - Department of Clinical Genetics, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Agnes Jager - Department of Medical Oncology, Family Cancer Clinic, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
Fred H. Menko - Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, the Netherlands
Marian J.E. Mourits - Department of Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
Christian F. Singer - Medical University of Vienna
Yen Y. Tan - Medical University of Vienna
Lenka Foretova - Masaryk Memorial Cancer Institute
Marie Navratilova - Masaryk Memorial Cancer Institute
Rita K. Schmutzler - University Hospital Cologne
Carolina Ellberg - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Anne-Marie Gerdes - Department of Clinical Genetics, Rigshospitalet, København, Denmark
Trinidad Caldes - Molecular Oncology Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Hospital Clínico San Carlos, Centro de Investigación Biomédica en Red de Cáncer, Martin Lagos, Madrid, Spain
Jacques Simard - Centre hospitalier universitaire de Québec
Edith Olah - Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary
Anna Jakubowska - Pomeranian Medical University
Johanna Rantala - Karolinska University Hospital
Ana Osorio - Human Genetics Group, Centro Nacional De Investigaciones Oncologicas, Madrid, Spain
John L. Hopper - The University of Melbourne
Kelly-Anne Phillips - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Roger L. Milne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Mary Beth Terry - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
Catherine Noguès - Département d’Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France
Christoph Engel - Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany
Karin Kast - University Hospital Carl Gustav Carus
David E. Goldgar - University of Utah
Flora E. van Leeuwen - Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Douglas F. Easton - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
Nadine Andrieu - Institut National de la Santé et de la Recherche Médicale, Paris, France
Matti A. Rookus - The Netherlands Cancer Institute
Catherine Noguès
Lilian Laborde
Pauline Pontois
Emanuelle Breysse
Margot Berline
Dominique Stoppa-Lyonnet
Marion Gauthier-Villars
Bruno Buecher
Chrystelle Colas
Olivier Caron
Emmanuelle Mouret-Fourme
Claire Saule
Jean-Pierre Fricker
Christine Lasset
Valérie Bonadona
Sophie Dussard
Pascaline Berthet
Laurence Faivre
Elisabeth Luporsi
Véronique Mari
Laurence Gladieff
Paul Gesta
Stéphanie Chieze-Valéro
Jessica Moretta
Hagay Sobol
François Eisinger
Cornel Popovici
Michel Longy
Louise Grivelli
Florent Soubrier
Patrick Benusiglio
Isabelle Coupier
Pascal Pujol
Carole Corsini
Marie-Emmanuelle Morin-Meschin
Alain Lortholary
Claude Adenis
Audrey Maillez
Tan Dat Nguyen
Capucine Delnatte
Caroline Abadie
Julie Tinat
Isabelle Tennevet
Christine Maugard
Yves-Jean Bignon
Mathilde Gay Bellile
Clotilde Penet
Hélène Dreyfus
Odile Cohen-Haguenauer
Brigitte Gilbert
Laurence Venat-Bouvet
Dominique Leroux
Clémentine Legrand
Hélène Zattara-Cannoni
Valérie Layet
Elodie Lacaze
Sandra Fert-Ferrer
Odile Bera
Brigitte Gilbert-Dussardier
David Tougeron
Hakima Lallaoui
M.A. Rookus
F.B.L. Hogervorst
F.E. van Leeuwen
M.A. Adank
M.K. Schmidt
D.J. Jenner
J.M. Collée
A.M.W. van den Ouweland
M.J. Hooning
I.A. Boere
C.J. van Asperen
P. Devilee
R.B. van der Luijt
T.C.T.E.F. van Cronenburg
M.R. Wevers
A.R. Mensenkamp
M.G.E.M. Ausems
M.J. Koudijs
I. van de Beek
K. van Engelen
J.J.P. Gille
E.B. Gómez García
M.J. Blok
M. de Boer
L.P.V. Berger
A.H. van der Hout
M.J.E. Mourits
Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International
G.H. de Bock
S. Siesling
J. Verloop
E.C. van den Broek
Détails de publication: American journal of obstetrics and gynecology, Vol.225(1), pp.51.e1-51.e17
Éditeur: Elsevier Inc
Note de subvention: Cancer Research UK (https://doi.org/10.13039/501100000289) National Center for Research and Development (https://doi.org/10.13039/501100011755) National Institute for Health Research (https://doi.org/10.13039/501100000272) German Cancer Aid (https://doi.org/10.13039/501100005972) Swedish Cancer Society (https://doi.org/10.13039/501100002794) Ministry of Economy and Competitiveness (https://doi.org/10.13039/501100003329) German Cancer Research Center (https://doi.org/10.13039/100008658) Biomedical Research Centre (https://doi.org/10.13039/100014461) Quebec Breast Cancer Foundation (https://doi.org/10.13039/100016328) European Research Council (https://doi.org/10.13039/501100000781)
Identifiants: 99158990209311
Unité académique: Maladies Infectieuses et Vecteurs : Ecologie, Génétique, Evolution et Contrôle - MIVEGEC
Langue: English
Type de ressource: Journal article